Your browser version may not work well with NCBI's Web applications. More information here...
1: Science. 2000 Sep 15;289(5486):1938-42.Click here to read Links
Comment in:
Science. 2000 Sep 15;289(5486):1857-9.

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.

Laboratories of Molecular Biophysics and Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.

The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-molecule inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Critical to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.

PMID: 10988075 [PubMed - indexed for MEDLINE]

Structures reported by this article

Patient Drug Information

  • Imatinib (Gleevec® )

    Imatinib is used to treat certain types of leukemia (cancer that begins in the white blood cells) and other cancers of the blood cells. Imatinib is also used to treat gastrointestinal stromal tumors (GIST; a type of tumo...

  • Source: AHFS Consumer Medication Information